FDA Approves METHOTREXATE — Fresenius Kabi USA, LLC
Fresenius Kabi USA announced the approval of its intrathecal formulation of METHOTREXATE, expanding the company’s portfolio of biosimilars and specialty infusion products. This approval may offer healthcare providers a new intrathecal option for patients, potentially driving revenue and strengthening market positioning in niche neuro-oncology.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed